A Rare Case of Adenoid Cystic Carcinoma of the Breast: A Case Report and Review of the Literature Adenoid Cystic Ca or ACC
Abstract
Background: Breast cancer is the second most commonly diagnosed cancer and leading cause of cancer-related death among women in the United States. Adenoid Cystic Carcinoma (AdCC) of the breast is a rare subtype, comprising less than 0.1% of cases. Despite its triple-negative profile, it typically carries a favorable prognosis.
Case Report: A 55-year-old Hispanic female presented for routine screening mammography. Initial imaging revealed fibroglandular densities and architectural distortion in the right breast (BI-RADS 0). Further evaluation identified an irregular 0.9 × 0.9 × 1.0 cm mass at the 12:30 position and an 18 mm lesion at 12:00, 2.5 cm from the nipple (BI-RADS 4). Lumpectomy and sentinel lymph node biopsy confirmed AdCC (pT2 N0). Radiation therapy was recommended; systemic therapy was not indicated.
Conclusion: This case highlights the rare presentation and diagnostic features of breast AdCC, contributing to the limited literature on this uncommon malignancy.
Full text article
References
Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res Treat. 2010;124(2):499–504.
Shin SJ, Rosen PP. Adenoid cystic carcinoma of the breast: an update. Arch Pathol Lab Med. 2002;126(6):714–20.
Geschickter CF, Copeland MM. Disease of the Breast. Philadelphia: W.B. Saunders Co.; 1945.
Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or "The strange case of Dr. Jekyll and Mr. Hyde" of exocrine gland carcinomas). J Clin Pathol. 2010;63(3):220–8.
Rosen PP. Adenoid cystic carcinoma. In: Rosen’s Breast Pathology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 545–52.
Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer. 2002;94(8):2119–27. doi:10.1002/cncr.10455
Li N, Xu L, Zhao H, et al. Clinicopathological features and outcomes of adenoid cystic carcinoma of the breast: a multicenter study. Sci Rep. 2020;10:10444.
Foschini MP, Reis-Filho JS, Eusebi V, Lakhani SR. Adenoid cystic carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012. p. 62–3.
Azoulay S, Laé M, Fréneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18(12):1623–31. doi:10.1038/modpathol.3800483
Coates JM, Martinez SR, Bold RJ, Chen SL. Adjuvant therapy for adenoid cystic carcinoma of the breast: justifiable? J Surg Oncol. 2010;102(4):353–6.
Miyai K, Schwartz MR, Divatia MK, et al. Adenoid cystic carcinoma of breast: recent advances. World J Clin Cases. 2014;2(12):732–41. doi:10.12998/wjcc.v2.i12.732
Liu L, Lin X, Xiang H, Tang G, Li C. Adenoid cystic carcinoma of the breast: a study of five cases. J Radiol Case Rep. 2020;14(11):16–25. doi:10.3941/jrcr.v14i11.3921
Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC. Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol. 2010;194(5):1391–6. doi:10.2214/AJR.09.3545
Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol. 2003;56(10):804. doi:10.1136/jcp.56.7.497
Ji J, Zhang F, Duan F, et al. Distinct clinicopathological and genomic features in solid and basaloid adenoid cystic carcinoma of the breast. Sci Rep. 2022;12(1):8504. doi:10.1038/s41598-022-12583-w
Schulz-Costello K, Fan F, Schmolze D, et al. Solid basaloid adenoid cystic carcinoma of the breast: a high-grade triple negative breast carcinoma which rarely responds to neoadjuvant chemotherapy. Hum Pathol. 2025;157:105760. doi:10.1016/j.humpath.2025.105760
Sanati S. Morphologic and molecular features of breast ductal carcinoma in situ. Am J Pathol. 2019;189(5):946–55. doi:10.1016/j.ajpath.2018.07.031
Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for C-Kit and P63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18(10):1277–82. doi:10.1038/modpathol.3800423
Nakai T, Ichihara S, Kada A, et al. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers. Virchows Arch. 2016;469(2):213–22. doi:10.1007/s00428-016-1963-4
Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24(2):157–67. doi:10.1038/modpathol.2010.200
Zhang W, Fang Y, Zhang Z, Wang J. Management of adenoid cystic carcinoma of the breast: a single-institution study. Front Oncol. 2021;11:621012. doi:10.3389/fonc.2021.621012
Pastolero G, Hanna W, Zbieranowski I, Kahn HJ. Proliferative activity and p53 expression in adenoid cystic carcinoma of the breast. Mod Pathol. 1996;9(3):215–9.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.